A novel hemostatic belt allowing ambulation soon after atrial fibrillation ablation

A novel hemostatic belt allowing ambulation soon after atrial fibrillation ablation - A novel hemostatic belt allowing ambulation soon after atrial fibrillation ablation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051594

Enrollment

Registered

2023-07-12

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Hemostasis of the right femoral venipuncture site with the use of the hemostatic belt Hemostasis of the right femoral venipuncture site with the use of the conventional compression bandage

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects with atrial fibrillation who were scheduled to undergo radiofrequency catheter ablation for the first time

Exclusion criteria

Exclusion criteria: Subjects with the hip circumference was >120 cm

Design outcomes

Primary

Measure	Time frame
Time from the onset of the application of the belt or compression bandage to ambulation	—

Secondary

Measure	Time frame
Satisfaction with the 2 hemostatic strategies on a scale of 1 to 10 (1=extremely dissatisfied, 10=extremely satisfied) (2) rebleeding or hematoma at the groin puncture site that required any medical attention or intervention including additional astriction, sutures, surgical intervention, or blood transfusion, and (3) adverse events resulting from the hemostatic strategies themselves such as skin problems, leg ischemia, or deep venous thrombosis	—

Measure

Time frame

Satisfaction with the 2 hemostatic strategies on a scale of 1 to 10 (1=extremely dissatisfied, 10=extremely satisfied) (2) rebleeding or hematoma at the groin puncture site that required any medical attention or intervention including additional astriction, sutures, surgical intervention, or blood transfusion, and (3) adverse events resulting from the hemostatic strategies themselves such as skin problems, leg ischemia, or deep venous thrombosis

—

Countries

Japan

Contacts

Public ContactAkinori Sairaku

National Hospital Organization Higashihiroshima Medical Center Cardiology

rjrgw059@ybb.ne.jp082-423-2176

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026